Previous 10 | Next 10 |
-- Strong U.S. commercial progress continues for IMCIVREE ® (setmelanotide) with more than 300 new prescriptions for Bardet-Biedl syndrome (BBS) received since FDA approval -- -- Launched IMCIVREE for BBS in Germany with federal reimbursement -- -- First patient...
2023-04-27 06:55:09 ET Eli Lilly ( NYSE: LLY ) announced Thursday that its experimental weight loss therapy, tirzepatide, generated up to 15.7% of weight loss, and the company expects the FDA to decide on its approval as early as late 2023. Tirzepatide, a glucose-dependent insul...
2023-04-24 17:17:27 ET Gainers: Medpace Holdings ( MEDP ) +27% . Jupiter Wellness Acquisition ( JWAC ) +4% . Rhythm Pharmaceuticals ( RYTM ) +3% . IDEAYA Biosciences ( IDYA ) +3% . Morphic Holding ( MORF ) +3% . Loser...
BOSTON, April 24, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway di...
BOSTON, April 18, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway di...
2023-04-10 10:48:10 ET A group of senior pharma executives, including Pfizer ( NYSE: PFE ) chief executive Albert Bourla, has come forward in support of the FDA after a Texas-based judge suspended the approval of abortion treatment mifepristone on Friday. Mifepristone, appro...
BOSTON, April 10, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway di...
2023-04-04 22:01:45 ET Summary Baker Brothers’ 13F portfolio value increased from $15.27B to $16.65B this quarter. Replimune Group stake was substantially increased this quarter. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they add up to alm...
2023-03-29 10:50:46 ET Weight loss therapies could be, for the first time, part of the World Health Organization's (WHO) "essential medicines list," which guides state procurement decisions in low- and middle-income countries, Reuters reported Wednesday, citing the U.N. agency. ...
- Interview-based research published in Advances in Therapy demonstrates setmelanotide improved hyperphagia and reduced body weight and obsessive focus on food – - Company also announces publication of health state utilities study in hyperphagia - BOSTON, March 27, 2023 (...
News, Short Squeeze, Breakout and More Instantly...
Rhythm Pharmaceuticals Inc. Company Name:
RYTM Stock Symbol:
NASDAQ Market:
Rhythm Pharmaceuticals Inc. Website:
BOSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced the appointment of Alastair “Al...
- European Commission decision anticipated in the second half of 2024 - BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rar...
2024-06-14 11:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...